Elsevier

Psychoneuroendocrinology

Volume 83, September 2017, Pages 101-110
Psychoneuroendocrinology

Sex-specific effects of intranasal oxytocin on thermal pain perception: A randomised, double-blind, placebo-controlled cross-over study

https://doi.org/10.1016/j.psyneuen.2017.05.028Get rights and content

Highlights

  • We examined effects of intranasal oxytocin (OT) on pain perception.

  • OT increased pain sensitivity in women with chronic neck and shoulder pain.

  • Men were more sensitive to pain at the cervical spine and deltoid.

  • Women were more sensitive to pain at the tibialis.

  • OT may have different effects on pain perception in men and women.

Abstract

Chronic neck and shoulder pain (CNSP) is a common musculoskeletal disorder in adults, which is linked to hypersensitivity to noxious stimuli. The hormone oxytocin has been implicated as a potential therapeutic for the management of chronic pain disorders, and has been suggested to have sex-specific effects on the salience of threatening stimuli. This study investigated the influence of intranasal oxytocin on the perception of noxious thermal stimuli. Participants were 24 individuals with CNSP lasting >12 months (eight women), and 24 age- and sex-matched healthy, pain-free controls. In a randomised double-blind, placebo-controlled, cross-over study, participants attended two sessions, self-administering intranasal oxytocin (24 IU) in one session, and placebo in another. Participants rated intensity and unpleasantness of thermal heat stimuli at three body sites: the cervical spine, deltoid, and tibialis anterior, on 11-point numerical rating scales. Compared with placebo, intranasal oxytocin increased the perceived intensity of noxious heat stimuli in women with CNSP (Cohen’s d = 0.71), but not in men with CNSP, or healthy, pain-free controls. Men and women displayed divergent sensitivity across target sites for ratings of pain intensity (partial eta squared = 0.12) and pain unpleasantness (partial eta squared = 0.24), irrespective of drug condition. Men were more sensitive at the cervical spine and deltoid, whereas women were more sensitive at the tibialis. These findings suggest that oxytocin and endogenous sex hormones may interact to influence the salience of noxious stimuli. The hyperalgesic effects of oxytocin in women suggest that caution should be taken when considering oxytocin in the management of chronic pain.

Trial Registration: CT-2016-CTN-01313-1; ACTRN12616000532404

Introduction

Chronic musculoskeletal neck-shoulder pain (CNSP) is a common disorder in working adults, with an estimated prevalence of 30–50% (Cote et al., 2009). Chronic pain in this body region has a significant impact on quality of life (Rezai et al., 2009) and causes substantial disability (Hoy et al., 2014). Families of those with CNSP are also impacted due to the physical and emotional changes associated with this chronic pain condition (West et al., 2012). In addition to the health and psychosocial burden of CNSP, there is a significant financial burden of CNSP due to sick leave and lost productivity (e.g., Hagberg et al., 2007). Persons with CNSP display hypersensitivity to noxious and innocuous stimuli, including reduced pain thresholds to experimental stimuli compared to controls (Van Oosterwijck et al., 2013), suggesting the presence of dysregulation in the processing of ascending nociceptive signals. However, these findings are inconsistent across studies (Coronado et al., 2014, Scott et al., 2005, Uthaikhup et al., 2015). A wide spectrum of interventions are used for the treatment of CNSP (e.g., surgery, opioid medications). Many of these treatments, however, have limited effectiveness, and are associated with increased risk of hyperalgesia (MacDermid et al., 2009). There is a clear need to develop novel effective treatments for CNSP.

Recent evidence suggests that the neuropeptide oxytocin decreases sensitivity to experimentally-induced pain in humans and animals that are otherwise pain-free (Rash et al., 2014). Consequently, oxytocin has been suggested as a potential treatment for chronic pain conditions (Tracy et al., 2015). Oxytocin is a peptide hormone produced within the nuclei of the hypothalamus (Sofroniew and Weindl, 1981) that is released into the peripheral circulation via the posterior pituitary gland (Carter et al., 2007, Uvnas-Moberg and Petersson, 2004). Traditionally, oxytocin is known for its peripheral actions involving contractions of uterine muscles during childbirth (Dale, 1906) and the “letdown reflex” during lactation (Ruis et al., 1981). However, there is also an extensive distribution of oxytocin receptors throughout the brain (especially in regions such as the anterior cingulate cortex, periaqueductal grey, and amygdala; MacDonald and MacDonald, 2010). Oxytocin has been shown to have a range of effects throughout the central nervous system. For instance, oxytocin has been implicated as a key regulator of social cognition and behaviour (Heinrichs et al., 2009), especially the processing of the salience of social and emotional information (Bartz et al., 2011, Shamay-Tsoory and Abu-Akel, 2016).

Sex-specific effects of intranasal oxytocin administration are evident, such that after intranasal oxytocin amygdala activation in response to presentation of fear-evoking stimuli is decreased in men (Kirsch et al., 2005), but increased in women (Domes et al., 2010). Whether these sex differences apply in relation to pain experience is not known. This is because previous studies have either examined the effects of oxytocin only in male rodents (e.g., Yang et al., 2011), and many studies in humans only recruited men (Paloyelis et al., 2016, Singer et al., 2008, Zunhammer et al., 2015), or if they recruited both men and women, they failed to analyse the data with respect to sex (Rash and Campbell, 2014). Therefore, while oxytocin seems to have a hypoalgesic effect, it remains unknown whether these effects are sex-specific, or if they occur in persons with chronic pain.

There are several potential mechanisms through which oxytocin may exert analgesic effects. One such mechanism is a direct hypothalamo-spinal projection from the paraventricular nucleus of the hypothalamus (a major site of endogenous oxytocin production) to the dorsal horn of the spinal cord (Gimpl and Fahrenholz, 2001), an area involved in the modulation of pain. Within the dorsal horn, there is a subset of neurons containing oxytocin receptors that influence glutamatergic neurons. These glutamatergic neurons, in turn, activate GABAergic neurons, leading to inhibition of pain-signalling A-delta (Aδ-) and C-fibers (e.g., Condes-Lara et al., 2009). A second potential mechanism involves the relationship between oxytocin and the endogenous opioid system (Han and Yu, 2009). In a rodent study, administration of oxytocin to the periaqueductal grey, which contains an opioid system that controls descending pathways that prevent pain signals traveling along the spinal cord (Melzack and Wall, 1988), resulted in reduced sensitivity to pain (Yang et al., 2011). These effects were subsequently blocked by the administration of an opioid receptor antagonist, thus highlighting their likely interactions with the opioid system within the periaqueductal grey.

Regardless of the exact mechanism, there is moderate evidence to suggest that oxytocin exerts analgesic effects. The strongest of this evidence comes from the animal literature, where 90% of the 33 studies included in a recent systematic review reported strong evidence for analgesic effects of oxytocin in response to acute, experimentally-induced pain (Rash et al., 2014). Importantly, 23 of these studies only tested male animals, three studies only tested female animals, and the remaining studies did not specify the sex of the animals. Testing was usually limited to males to avoid variability in behaviour thought to accompany the oestrous cycle (Ochedalski et al., 2007). Despite prominent effects in these preclinical studies, the evaluation of analgesic effects of intranasal oxytocin in humans have yielded mixed results. Rash and Campbell (2014) reported that intranasal oxytocin reduced behavioural and physiological reactions in response to cold-pressor pain in young, pain-free men and women. Zunhammer et al. (2015) reported that intranasal oxytocin reduced subjective pain intensity ratings in response to the delivery of thermal heat stimuli in pain-free men, but there was no effect on thermal heat pain thresholds. In contrast, Singer et al. (2008) reported no effect of intranasal oxytocin on the unpleasantness of experimentally-induced electrical pain in healthy, pain-free men (intensity ratings were not collected). Only a handful of studies have investigated the analgesic effect of intranasal oxytocin in persons with chronic pain, including fibromyalgia (Mameli et al., 2014), and irritable bowel syndrome (Ohlsson et al., 2005), but failed to observe any analgesic effects. To date, no studies have examined the potential analgesic effects of intranasal oxytocin in individuals with CNSP, and whether the effects of oxytocin vary in comparison with persons who don’t have chronic pain, or between men and women.

The current study was designed to investigate the differences in sensitivity to noxious thermal heat pain stimuli across the body in individuals with CNSP and healthy, pain-free controls. We hypothesised that (1) individuals with CNSP would provide higher ratings of pain intensity and pain unpleasantness in comparison to healthy, pain-free controls, particularly at sites proximal to their chronic pain (i.e., the cervical spine), (2) that intranasal oxytocin would decrease the sensitivity to pain in both groups, compared to placebo, and (3) that intranasal oxytocin, compared to placebo, would increase sensitivity to noxious thermal heat stimuli in women, but decrease sensitivity to noxious stimuli in men.

Section snippets

Study design

This study employed a randomised, double-blind, placebo-controlled cross-over design adhering to CONSORT guidelines (Moher et al., 2012). Each participant was tested under two acute treatment conditions separated by a washout period of at least 14 days (mean days between testing sessions = 16.3; range = 14–36). There are several advantages to this design. First, there is a reduction in the influence of potential extraneous confounding factors (e.g., age and sex of participants), as each participant

Sample description

Forty-eight participants (16 women, seven of whom were using hormone-based contraceptives) completed the study and were included in analyses. A detailed inclusion diagram, according to the CONSORT criteria, is provided in Figures A.1 and A.2. In total, 12 participants reported side effects over the two sessions. Five participants reported side effects following oxytocin administration, including calmness (n = 3), drowsiness (n = 3), euphoria (n = 1), and nasal irritation (n = 1). Nine participants

General discussion

To the best of our knowledge, this is the first study to test the effects of intranasal oxytocin on thermal heat pain perception in persons with chronic musculoskeletal neck and shoulder pain. Contrary to our expectation that oxytocin would have an analgesic effect (i.e., reducing the subjective ratings of pain intensity and pain unpleasantness in individuals with CNSP), the results showed that intranasal oxytocin (compared to placebo) increased the perceived intensity of noxious thermal heat

Author contributions

Each co-author contributed significantly to the work described and commented on the manuscript. LMT planned and executed the study, recruited and gained consent from participants, collected and analysed data, discussed the results, and wrote the manuscript with guidance and feedback from the co-authors. IL contributed to the planning of the study, discussion of the results, and editing the manuscript. NG-K contributed to the research design, interpretation of analyses, discussion of results,

Declaration of interest and funding sources

The authors have no conflict of interest to declare. This study was funded by an Australian Research Council Linkage Project Grant (LP120200033) between the Victorian Transport Accident Commission and the School of Psychological Sciences, Monash University. MJG was supported by a National Health and Medical Research Council Early Career Researcher Fellowship (APP1036124). LMT was supported by an Australian Government Research Training Program Scholarship. This was an investigator-initiated

Notes

Portions of this dataset were presented at the 37th Annual Scientific Meeting of the Australian Pain Society.

Acknowledgements

The authors would like to thank Dr Katrina Simpson for her assistance with statistical analysis, and the Australian Pain Management Association and the Melbourne Whiplash Centre for their assistance with participant identification and recruitment. The authors would also like to thank the two anonymous reviewers who provided detailed feedback on earlier versions of this manuscript.

References (77)

  • Y. Han et al.

    Involvement of oxytocin and its receptor in nociceptive modulation in the central nucleus of amygdala of rats

    Neurosci. Lett.

    (2009)
  • M. Heinrichs et al.

    Oxytocin, vasopressin, and human social behavior

    Front. Neuroendocrinol.

    (2009)
  • M.L. Loggia et al.

    Autonomic responses to heat pain: heart rate, skin conductance, and their relation to verbal ratings and stimulus intensity

    Pain

    (2011)
  • E. MacDonald et al.

    A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research

    Psychoneuroendocrinology

    (2011)
  • D. Moher et al.

    CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials

    Int. J. Surg.

    (2012)
  • D.D. Price et al.

    The validation of visual analogue scales as ratio scale measures for chronic and experimental pain

    Pain

    (1983)
  • M. Racine et al.

    A systematic literature review of 10 years of research on sex/gender and experimental pain perception − part 1: Are there really differences between women and men?

    Pain

    (2012)
  • F. Sanna et al.

    Oxytocin-induced yawning: sites of action in the brain and interaction with mesolimbic/mesocortical and incertohypothalamic dopaminergic neurons in male rats

    Horm. Behav.

    (2012)
  • S.G. Shamay-Tsoory et al.

    The social salience hypothesis of oxytocin

    Biol. Psychiatry

    (2016)
  • M.V. Sofroniew et al.

    CNS distribution of vasopressin and oxytocin

  • M. Sterling et al.

    Physical and psychological factors predict outcome following whiplash injury

    Pain

    (2005)
  • M. Sterling

    Differential development of sensory hypersensitivity and a measure of spinal cord hyperexcitability following whiplash injury

    Pain

    (2010)
  • L.M. Tracy et al.

    Oxytocin and the modulation of pain experience: implications for chronic pain management

    Neurosci. Biobehav. Rev.

    (2015)
  • H. Walum et al.

    Statistical and methodological considerations for the interpretation of intranasal oxytocin studies

    Biol. Psychiatry

    (2016)
  • J. Yang et al.

    Oxytocin in the periaqueductal gray participates in pain modulation in the rat by influencing endogenous opiate peptides

    Peptides

    (2011)
  • A.T. Beck et al.

    Manual for the Beck Anxiety Inventory

    (1990)
  • A.T. Beck et al.

    Comparison of beck depression inventories −IA and −II in psychiatric outpatients

    J. Pers. Assess.

    (1996)
  • A.T. Beck et al.

    Beck Depression Inventory

    (1996)
  • K.C. Berridge

    The debate over dopamine's role in reward: the case for incentive salience

    Psychopharmacology

    (2007)
  • C.S. Carter et al.

    Oxytocin: behavioral associations and potential as a salivary biomarker

    Ann. N. Y. Acad. Sci.

    (2007)
  • C.S. Cleeland et al.

    Pain assessment: global use of the brief pain inventory

    Ann. Acad. Med. Singapore

    (1994)
  • C.S. Cleeland

    The Brief Pain Inventory User Guide

    (2009)
  • R.A. Coronado et al.

    Experimental pain responses support peripheral and central sensitization in patients with unilateral shoulder pain

    Clin. J. Pain

    (2014)
  • P. Cote et al.

    The burden and determinants of neck pain in workers: results of the bone and joint decade 2000–2010 Task Force on Neck Pain and Its Associated Disorders

    J. Manipulative Physiol. Ther.

    (2009)
  • H.H. Dale

    On some physiological actions of ergot

    J. Physiol. (Lond.)

    (1906)
  • M. Davidson et al.

    A twelve-item symptom intensity rating scale for cervical spine dysfunction

    Spine

    (2011)
  • C. Dickens et al.

    Impact of depression on experimental pain perception: a systematic review of the literature with meta-analysis

    Psychosom. Med.

    (2003)
  • O.J. Dunn

    Multiple comparisons among means

    J. Am. Stat. Assoc.

    (1961)
  • Cited by (15)

    • Effects of intranasal oxytocin on pain perception among human subjects: A systematic literature review and meta-analysis

      2023, Hormones and Behavior
      Citation Excerpt :

      Almost one-third of the samples (N = 8) presented significant differences in pain intensity. Six studies reported that OXT decreased pain perception (Rash et al., 2014; Paloyelis et al., 2016; Boll et al., 2020 – only for induced pain in the clinical group; Flynn et al., 2021 – only after two weeks; Pfeifer et al. (2020) only among men; Skvortsova et al., 2020 – only in learning phase), while two studies reported increased pain perception (Tracy et al., 2017- only among women in the clinical group; Pfeifer et al., 2020 – only among women). However, the meta-analysis measure of the effect size of the different samples revealed a lack of significant differences between OXT and placebo in pain intensity (SMD = −0.02 (CI 95 %: −0.17 to 0.12; p = 0.75); I2 = 24.86 %, p = 0.31; equivalence test significant: effect size: -0.02; IC 90 % (−0.15 to 0.011, p = 0.008)).

    • Intranasal oxytocin and the stress-buffering effects of social support during experimentally induced pain: The role of attachment security

      2021, Journal of Affective Disorders
      Citation Excerpt :

      More specifically, Kreuder et al. (2019) showed that intranasal oxytocin modulates the pain-relieving effect of social support in romantic couples, possibly by increasing trust toward close others. Moreover, oxytocin may also have analgesic properties (Louvel et al., 1996; Rash et al., 2014; Zunhammer et al., 2016, but see Kessner et al., 2013; Mameli et al., 2014; Tracy et al., 2017; Skvortsova et al., 2018) and affects autonomic nervous system (ANS) responses to aversive stimuli such as psychological or physical stressors (Kubansky et al., 2012; Tracy et al., 2018). Acute experimentally induced pain results in reduced parasympathetic activity (Koenig et al., 2014), but intranasal oxytocin administration attenuates autonomic response to stressors, including a flattened parasympathetic withdrawal and lower increases in sympathetic activation in response to stress (Kubansky et al., 2012).

    • Oxytocin Effects on Pain Perception and Pain Anticipation

      2019, Journal of Pain
      Citation Excerpt :

      The final sample included 46 male subjects for behavior and functional magnetic resonance imaging (fMRI; OT, n = 23) and 38 subjects for SCR owing to missing data (OT, n = 20). A homogeneous group of male subjects was selected owing to OT effects having been shown to be highly sex sensitive.38 All participants provided written, informed consent.

    • Intranasal oxytocin reduces heart rate variability during a mental arithmetic task: A randomised, double-blind, placebo-controlled cross-over study

      2018, Progress in Neuro-Psychopharmacology and Biological Psychiatry
      Citation Excerpt :

      Furthermore, while the current study was powered in accordance with previous study findings to detect main effects of oxytocin in persons with CNSP, it was underpowered to adequately examine sex-specific effects of intranasal oxytocin on HRV. Previous studies have reported sex differences in resting HRV (Koenig and Thayer, 2016) and sex-specific effects of intranasal oxytocin administration (Domes et al., 2010; Kirsch et al., 2005; Tracy et al., 2017b). Future studies are required to examine sex-specific effects of intranasal oxytocin on HRV with a larger sample of both men and women; and to examine if hormonal contraceptive use in women could alter the effects of intranasal oxytocin, or induce an increase in the level of oxytocin, as reported in previous research (Scheele et al., 2016; Silber et al., 1987).

    • Effects of Oxytocin on Placebo and Nocebo Effects in a Pain Conditioning Paradigm: A Randomized Controlled Trial

      2020, Journal of Pain
      Citation Excerpt :

      A lot of research focused on possible analgesic effects of oxytocin, but the results remain contradictory. A number of studies found pain reducing effects of oxytocin,7,33,45 however, others could not replicate these results.22,28,38,41 A few limitations of the current study should be mentioned.

    View all citing articles on Scopus
    View full text